MPOX TRACKER

SIGA Technologies, Inc. (NASDAQ: SIGA), a leader in infectious disease pharmaceuticals, has announced a significant milestone in its global expansion efforts. The company has entered into an agreement to supply TPOXX (tecovirimat) to Morocco, marking its first commercial sale of the antiviral therapy in Africa.

This agreement comes in response to a request from Morocco's Ministry of Health to bolster the country's preparedness against potential mpox outbreaks. While TPOXX has been available in Africa through clinical trials and the World Health Organization's emergency use access protocol, this deal represents a new phase in the drug's availability on the continent.

TPOXX, already approved in the United States, Canada, and the European Union, is an antiviral medicine primarily used for treating smallpox. In Europe and the UK, it's also authorized for treating mpox, cowpox, and vaccinia complications.

Victor Gomes, Vice President of International Markets at SIGA, expressed pride in providing access to TPOXX in Morocco. He emphasized the company's commitment to expanding its global presence and ensuring patient access to the therapy. Gomes also highlighted the strong collaboration with Morocco's Ministry of Health in achieving a quick delivery of TPOXX.

Looking ahead, SIGA aims to work with countries and organizations across Africa to contribute to the advancement of global health. The company's mission extends beyond mpox, focusing on protecting humanity against the world's most severe infectious diseases, whether they occur naturally, accidentally, or intentionally.

As a commercial-stage pharmaceutical company, SIGA's efforts in Morocco align with its broader goal of building a healthier and safer world through essential countermeasures against global health threats. This agreement not only expands TPOXX's reach but also strengthens Morocco's preparedness against potential infectious disease outbreaks.